{"transactions":[{"id":720907,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Share Option (Right to Buy)","published_at":"2026-07-01T20:11:13.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Share options vest in twelve equal monthly installments commencing on July 29, 2026."}],"balance_after":47500,"derivative":{"exercise_price":1.61,"expiration_date":"2036-06-29","underlying":"American Depositary Shares","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001730463-26-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000173046326000097/form4.xml","form_type":"4"}},{"id":720906,"issuer":{"id":1933,"kind":"organization","name":"Autolus Therapeutics plc","symbol":"AUTL"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Restricted Share Units","published_at":"2026-07-01T20:11:13.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in one installment on June 29, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in one installment on June 29, 2027."}],"balance_after":31667,"derivative":{"underlying":"American Depositary Shares","underlying_shares":31667},"source":{"system":"sec-edgar","filing":"0001730463-26-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000173046326000097/form4.xml","form_type":"4"}},{"id":727626,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2026-06-24T14:00:08.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":8000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001437749-26-021513","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926021513/rdgdoc.xml","form_type":"4"}},{"id":727625,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2026-06-24T14:00:08.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":34.99,"expiration_date":"2036-06-22","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-26-021513","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926021513/rdgdoc.xml","form_type":"4"}},{"id":728765,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:29:12.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001222082-26-000004","document":"form4-06232026_090608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000122208226000004/form4-06232026_090608.xml","form_type":"4"}},{"id":985074,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2025-12-01T21:52:32.000Z","date":"2025-11-26","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":6000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001437749-25-036565","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925036565/rdgdoc.xml","form_type":"4"}},{"id":985073,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"ordinary shares","published_at":"2025-12-01T21:52:32.000Z","date":"2025-11-26","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001437749-25-036565","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925036565/rdgdoc.xml","form_type":"4"}},{"id":1054534,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2025-08-27T20:37:58.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":8000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001437749-25-027879","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925027879/rdgdoc.xml","form_type":"4"}},{"id":1054533,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2025-08-27T20:37:58.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":19.5,"expiration_date":"2035-08-26","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-25-027879","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925027879/rdgdoc.xml","form_type":"4"}},{"id":1109902,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-16T22:23:57.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":44000,"derivative":{"exercise_price":0.6,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001062993-25-011783","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850119/000106299325011783/form4.xml","form_type":"4"}},{"id":1111290,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:16.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017233","document":"form4-06132025_050612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000141588925017233/form4-06132025_050612.xml","form_type":"4"}},{"id":1437863,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2024-08-08T13:06:59.000Z","date":"2024-08-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":15.16,"expiration_date":"2034-08-06","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-24-025291","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774924025291/rdgdoc.xml","form_type":"4"}},{"id":1472179,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T20:50:41.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":44000,"derivative":{"exercise_price":2.69,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001062993-24-012904","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850119/000106299324012904/form4.xml","form_type":"4"}},{"id":1474964,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T21:00:10.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":23000,"derivative":{"exercise_price":12.36,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-24-017441","document":"form4-06182024_050605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000141588924017441/form4-06182024_050605.xml","form_type":"4"}},{"id":1784656,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Stock Option (right ot buy)","published_at":"2023-09-08T19:43:15.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":16.85,"expiration_date":"2033-09-07","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-23-025485","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923025485/rdgdoc.xml","form_type":"4"}},{"id":1842077,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-29T20:20:59.000Z","date":"2023-06-27","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":44000,"derivative":{"exercise_price":3.19,"expiration_date":"2024-06-27","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001062993-23-014169","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850119/000106299323014169/form4.xml","form_type":"4"}},{"id":1847641,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:14.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":7.84,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-23-010101","document":"form4-06212023_050603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000141588923010101/form4-06212023_050603.xml","form_type":"4"}},{"id":2221018,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T21:12:28.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"date","element":"transactionDate","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.61,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006962","document":"form4a-06272022_020617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000141588922006962/form4a-06272022_020617.xml","form_type":"4/A","original_submission_date":"2022-06-17"}},{"id":2227288,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T23:25:28.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.43,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006781","document":"form4-06172022_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000141588922006781/form4-06172022_040613.xml","form_type":"4"}},{"id":2236321,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:23:59.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19872,"derivative":{"exercise_price":8.56,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":19872},"source":{"system":"sec-edgar","filing":"0001062993-22-014659","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850119/000106299322014659/form4.xml","form_type":"4"}},{"id":2235929,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T19:37:32.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":7.06,"expiration_date":"2032-06-08","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001437749-22-014773","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922014773/rdgdoc.xml","form_type":"4"}},{"id":2661497,"issuer":{"id":5739,"kind":"organization","name":"Century Therapeutics, Inc.","symbol":"IPSC"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-21T20:32:54.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":19872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of (a) June 17, 2022 or (b) the next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19872,"derivative":{"exercise_price":20,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":19872},"source":{"system":"sec-edgar","filing":"0001192482-21-000559","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850119/000119248221000559/edgar.xml","form_type":"4"}},{"id":2673636,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-10T22:36:51.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":27.66,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-21-002925","document":"form4-06102021_030639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000141588921002925/form4-06102021_030639.xml","form_type":"4"}},{"id":2675681,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:44:27.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":17.98,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-039135","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039135/doc4.xml","form_type":"4"}},{"id":2972904,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:42:17.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001209191-20-059510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919120059510/doc4.xml","form_type":"4"}},{"id":2972903,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:42:17.000Z","date":"2020-09-16","kind":"exercise","acquired":false,"shares":83876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 36 successive equal monthly installments measured from August 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.406,"expiration_date":"2030-08-11","underlying":"Common Stock","underlying_shares":83876},"source":{"system":"sec-edgar","filing":"0001209191-20-059510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919120059510/doc4.xml","form_type":"4"}},{"id":2972902,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:42:17.000Z","date":"2020-08-12","kind":"grant","acquired":true,"shares":83876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 36 successive equal monthly installments measured from August 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable."}],"balance_after":83876,"derivative":{"exercise_price":4.406,"expiration_date":"2030-08-11","underlying":"Common Stock","underlying_shares":83876},"source":{"system":"sec-edgar","filing":"0001209191-20-059510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919120059510/doc4.xml","form_type":"4"}},{"id":2972901,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T23:42:17.000Z","date":"2020-09-16","kind":"exercise","acquired":true,"shares":83876,"price":4.406,"value":369557.656,"ownership":{"direct":true},"balance_after":83876,"source":{"system":"sec-edgar","filing":"0001209191-20-059510","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919120059510/doc4.xml","form_type":"4"}},{"id":3114834,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-10T22:36:27.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":28.24,"expiration_date":"2030-06-07","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-035677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120035677/doc4.xml","form_type":"4"}},{"id":3500641,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-05T20:58:22.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of two years."}],"balance_after":10000,"derivative":{"exercise_price":34.83,"expiration_date":"2029-06-02","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-034788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119034788/doc4.xml","form_type":"4"}},{"id":4190894,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":90600,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":46.09,"expiration_date":"2026-12-21","underlying":"Common Stock","underlying_shares":90600},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190893,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":37181,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":37181},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190892,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":28919,"price":116.13,"value":3358363.47,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":28919},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190891,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":23437,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":51.96,"expiration_date":"2024-12-23","underlying":"Common Stock","underlying_shares":23437},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190890,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":51563,"price":128.04,"value":6602126.52,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":51.96,"expiration_date":"2024-12-23","underlying":"Common Stock","underlying_shares":51563},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190889,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":28034,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provided for 25% vesting on June 20, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2024-06-19","underlying":"Common Stock","underlying_shares":28034},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190888,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":121477,"price":163,"value":19800751.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provided for 25% vesting on June 20, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2024-06-19","underlying":"Common Stock","underlying_shares":121477},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190887,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":36284,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option provided for vesting as to 108,839 shares on December 15, 2017 and vesting as to 9,071 shares per month thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-24","underlying":"Common Stock","underlying_shares":36284},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190886,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":44110,"price":178.65,"value":7880251.5,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option provided for vesting as to 108,839 shares on December 15, 2017 and vesting as to 9,071 shares per month thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-24","underlying":"Common Stock","underlying_shares":44110},"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190885,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-10-06T00:11:55.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":93667,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"date","element":"transactionDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 38,675 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a \"Company Restricted Stock Unit\"), held by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4190884,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-10-06T00:11:55.000Z","date":"2017-09-21","kind":"gift","acquired":false,"shares":27900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":93667,"source":{"system":"sec-edgar","filing":"0001209191-17-056216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117056216/doc4.xml","form_type":"4"}},{"id":4200805,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-09-28T01:38:49.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":4228,"price":179.6639,"value":759618.9692,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU."}],"balance_after":121567,"source":{"system":"sec-edgar","filing":"0001209191-17-054194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117054194/doc4.xml","form_type":"4"}},{"id":4200804,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-09-28T01:38:49.000Z","date":"2017-09-25","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125795,"source":{"system":"sec-edgar","filing":"0001209191-17-054194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117054194/doc4.xml","form_type":"4"}},{"id":4235105,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-08-14T21:03:03.000Z","date":"2017-08-10","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":80394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-048785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117048785/doc4.xml","form_type":"4"}},{"id":4235104,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-08-14T21:03:03.000Z","date":"2017-08-10","kind":"sale","acquired":false,"shares":5800,"price":121.03,"value":701974.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.82 to $141.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-048785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117048785/doc4.xml","form_type":"4"}},{"id":4235103,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-08-14T21:03:03.000Z","date":"2017-08-10","kind":"sale","acquired":false,"shares":9200,"price":120.52,"value":1108784.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.79 to $120.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":123595,"source":{"system":"sec-edgar","filing":"0001209191-17-048785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117048785/doc4.xml","form_type":"4"}},{"id":4235102,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-08-14T21:03:03.000Z","date":"2017-08-10","kind":"exercise","acquired":true,"shares":15000,"price":1.35,"value":20250.0,"ownership":{"direct":true},"balance_after":132795,"source":{"system":"sec-edgar","filing":"0001209191-17-048785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117048785/doc4.xml","form_type":"4"}},{"id":4258961,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-07-11T21:36:57.000Z","date":"2017-07-10","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":95394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-044804","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117044804/doc4.xml","form_type":"4"}},{"id":4258960,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-07-11T21:36:57.000Z","date":"2017-07-10","kind":"sale","acquired":false,"shares":5000,"price":105.5,"value":527500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117044804/doc4.xml","form_type":"4"}},{"id":4258959,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-07-11T21:36:57.000Z","date":"2017-07-10","kind":"sale","acquired":false,"shares":1100,"price":102.81,"value":113091.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.67 to $103.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":122795,"source":{"system":"sec-edgar","filing":"0001209191-17-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117044804/doc4.xml","form_type":"4"}},{"id":4258958,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-07-11T21:36:57.000Z","date":"2017-07-10","kind":"sale","acquired":false,"shares":5553,"price":102.19,"value":567461.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.65 to $102.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":123895,"source":{"system":"sec-edgar","filing":"0001209191-17-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117044804/doc4.xml","form_type":"4"}},{"id":4258957,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-07-11T21:36:57.000Z","date":"2017-07-10","kind":"sale","acquired":false,"shares":3347,"price":101.06,"value":338247.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.65 to $101.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":129448,"source":{"system":"sec-edgar","filing":"0001209191-17-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117044804/doc4.xml","form_type":"4"}},{"id":4258956,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-07-11T21:36:57.000Z","date":"2017-07-10","kind":"exercise","acquired":true,"shares":15000,"price":1.35,"value":20250.0,"ownership":{"direct":true},"balance_after":132795,"source":{"system":"sec-edgar","filing":"0001209191-17-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117044804/doc4.xml","form_type":"4"}},{"id":4271579,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-06-27T23:07:30.000Z","date":"2017-06-23","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This report is being amended to include the same day exercise of an option that was inadvertently omitted from the initial Form 4 filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":110394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-17-042042","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117042042/doc4a.xml","form_type":"4/A","original_submission_date":"2017-06-27"}},{"id":4271578,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-27T23:07:30.000Z","date":"2017-06-23","kind":"sale","acquired":false,"shares":2050,"price":101.19,"value":207439.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These sales, although previously reported, are being included in this amendment simply to reflect the correct end of period holdings as a result of the option exercise reflected herein."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.01 to $101.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These sales, although previously reported, are being included in this amendment simply to reflect the correct end of period holdings as a result of the option exercise reflected herein."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-042042","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117042042/doc4a.xml","form_type":"4/A","original_submission_date":"2017-06-27"}},{"id":4271577,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-27T23:07:30.000Z","date":"2017-06-23","kind":"sale","acquired":false,"shares":2950,"price":100.54,"value":296593.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These sales, although previously reported, are being included in this amendment simply to reflect the correct end of period holdings as a result of the option exercise reflected herein."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These sales, although previously reported, are being included in this amendment simply to reflect the correct end of period holdings as a result of the option exercise reflected herein."}],"balance_after":119845,"source":{"system":"sec-edgar","filing":"0001209191-17-042042","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117042042/doc4a.xml","form_type":"4/A","original_submission_date":"2017-06-27"}},{"id":4271576,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-27T23:07:30.000Z","date":"2017-06-23","kind":"exercise","acquired":true,"shares":5000,"price":1.35,"value":6750.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This report is being amended to include the same day exercise of an option that was inadvertently omitted from the initial Form 4 filing."}],"balance_after":122795,"source":{"system":"sec-edgar","filing":"0001209191-17-042042","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117042042/doc4a.xml","form_type":"4/A","original_submission_date":"2017-06-27"}},{"id":4271575,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-27T16:25:24.000Z","date":"2017-06-23","kind":"sale","acquired":false,"shares":2050,"price":101.19,"value":207439.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.01 to $101.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":112795,"source":{"system":"sec-edgar","filing":"0001209191-17-041909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117041909/doc4.xml","form_type":"4"}},{"id":4271574,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-27T16:25:24.000Z","date":"2017-06-23","kind":"sale","acquired":false,"shares":2950,"price":100.54,"value":296593.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":114845,"source":{"system":"sec-edgar","filing":"0001209191-17-041909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117041909/doc4.xml","form_type":"4"}},{"id":4285324,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":115394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4285323,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"sale","acquired":false,"shares":400,"price":91.08,"value":36432.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.94 to $91.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4285322,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"sale","acquired":false,"shares":1698,"price":89.76,"value":152412.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.38 to $90.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":118195,"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4285321,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"sale","acquired":false,"shares":4100,"price":89.09,"value":365269.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.38 to $89.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":119893,"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4285320,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"sale","acquired":false,"shares":2502,"price":87.8,"value":219675.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.31 to $88.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":123993,"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4285319,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"sale","acquired":false,"shares":900,"price":86.42,"value":77778.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.04 to $86.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":126495,"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4285318,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"sale","acquired":false,"shares":400,"price":84.81,"value":33924.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.40 to $85.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":127395,"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4285317,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-06-12T23:16:54.000Z","date":"2017-06-09","kind":"exercise","acquired":true,"shares":10000,"price":1.35,"value":13500.0,"ownership":{"direct":true},"balance_after":127795,"source":{"system":"sec-edgar","filing":"0001209191-17-039289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117039289/doc4.xml","form_type":"4"}},{"id":4343420,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-04-27T22:49:24.000Z","date":"2017-04-25","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":125394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-028501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117028501/doc4.xml","form_type":"4"}},{"id":4343419,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-27T22:49:24.000Z","date":"2017-04-25","kind":"sale","acquired":false,"shares":3742,"price":82.87,"value":310099.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.53 to $83.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-028501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117028501/doc4.xml","form_type":"4"}},{"id":4343418,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-27T22:49:24.000Z","date":"2017-04-25","kind":"sale","acquired":false,"shares":5545,"price":82.14,"value":455466.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.53 to $82.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":121537,"source":{"system":"sec-edgar","filing":"0001209191-17-028501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117028501/doc4.xml","form_type":"4"}},{"id":4343417,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-27T22:49:24.000Z","date":"2017-04-25","kind":"sale","acquired":false,"shares":5713,"price":80.89,"value":462124.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.47 to $81.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":127082,"source":{"system":"sec-edgar","filing":"0001209191-17-028501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117028501/doc4.xml","form_type":"4"}},{"id":4343416,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-27T22:49:24.000Z","date":"2017-04-25","kind":"exercise","acquired":true,"shares":15000,"price":1.35,"value":20250.0,"ownership":{"direct":true},"balance_after":132795,"source":{"system":"sec-edgar","filing":"0001209191-17-028501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117028501/doc4.xml","form_type":"4"}},{"id":4360462,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-04-04T20:15:58.000Z","date":"2017-04-03","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":140394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-17-024739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117024739/doc4.xml","form_type":"4"}},{"id":4360461,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-04T20:15:58.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":100,"price":84.22,"value":8422.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-024739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117024739/doc4.xml","form_type":"4"}},{"id":4360460,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-04T20:15:58.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":700,"price":83.46,"value":58422.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.93 to $83.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117895,"source":{"system":"sec-edgar","filing":"0001209191-17-024739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117024739/doc4.xml","form_type":"4"}},{"id":4360459,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-04T20:15:58.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":2400,"price":82.38,"value":197712.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.86 to $82.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":118595,"source":{"system":"sec-edgar","filing":"0001209191-17-024739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117024739/doc4.xml","form_type":"4"}},{"id":4360458,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-04T20:15:58.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":1800,"price":80.69,"value":145242.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.50 to $80.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":120995,"source":{"system":"sec-edgar","filing":"0001209191-17-024739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117024739/doc4.xml","form_type":"4"}},{"id":4360457,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-04-04T20:15:58.000Z","date":"2017-04-03","kind":"exercise","acquired":true,"shares":5000,"price":1.35,"value":6750.0,"ownership":{"direct":true},"balance_after":122795,"source":{"system":"sec-edgar","filing":"0001209191-17-024739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117024739/doc4.xml","form_type":"4"}},{"id":4370143,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-03-28T23:57:12.000Z","date":"2017-03-27","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":145394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-023211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117023211/doc4.xml","form_type":"4"}},{"id":4370142,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-28T23:57:12.000Z","date":"2017-03-27","kind":"sale","acquired":false,"shares":400,"price":78.75,"value":31500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.72 to $78.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-023211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117023211/doc4.xml","form_type":"4"}},{"id":4370141,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-28T23:57:12.000Z","date":"2017-03-27","kind":"sale","acquired":false,"shares":4925,"price":78.1,"value":384642.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.66 to $78.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":118195,"source":{"system":"sec-edgar","filing":"0001209191-17-023211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117023211/doc4.xml","form_type":"4"}},{"id":4370140,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-28T23:57:12.000Z","date":"2017-03-27","kind":"sale","acquired":false,"shares":4375,"price":77.23,"value":337881.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.55 to $77.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":123120,"source":{"system":"sec-edgar","filing":"0001209191-17-023211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117023211/doc4.xml","form_type":"4"}},{"id":4370139,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-28T23:57:12.000Z","date":"2017-03-27","kind":"sale","acquired":false,"shares":300,"price":75.74,"value":22722.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.28 to $75.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":127495,"source":{"system":"sec-edgar","filing":"0001209191-17-023211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117023211/doc4.xml","form_type":"4"}},{"id":4370138,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-28T23:57:12.000Z","date":"2017-03-27","kind":"exercise","acquired":true,"shares":10000,"price":1.35,"value":13500.0,"ownership":{"direct":true},"balance_after":127795,"source":{"system":"sec-edgar","filing":"0001209191-17-023211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117023211/doc4.xml","form_type":"4"}},{"id":4390517,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-03-10T22:25:44.000Z","date":"2017-03-09","kind":"exercise","acquired":false,"shares":21118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":155394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":21118},"source":{"system":"sec-edgar","filing":"0001209191-17-019920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117019920/doc4.xml","form_type":"4"}},{"id":4390516,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-10T22:25:44.000Z","date":"2017-03-09","kind":"sale","acquired":false,"shares":8991,"price":81.2,"value":730069.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.01 to $81.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-019920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117019920/doc4.xml","form_type":"4"}},{"id":4390515,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-10T22:25:44.000Z","date":"2017-03-09","kind":"sale","acquired":false,"shares":12127,"price":80.47,"value":975859.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":126786,"source":{"system":"sec-edgar","filing":"0001209191-17-019920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117019920/doc4.xml","form_type":"4"}},{"id":4390514,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-10T22:25:44.000Z","date":"2017-03-09","kind":"exercise","acquired":true,"shares":21118,"price":1.35,"value":28509.3,"ownership":{"direct":true},"balance_after":138913,"source":{"system":"sec-edgar","filing":"0001209191-17-019920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117019920/doc4.xml","form_type":"4"}},{"id":4413603,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-03-02T02:59:52.000Z","date":"2017-03-01","kind":"exercise","acquired":false,"shares":28882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":176512,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":28882},"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413602,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-03-02T02:59:52.000Z","date":"2017-02-27","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":205394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413601,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":28882,"price":80.05,"value":2312004.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413600,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-03-01","kind":"exercise","acquired":true,"shares":28882,"price":1.35,"value":38990.7,"ownership":{"direct":true},"balance_after":146677,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413599,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":690,"price":56.83,"value":39212.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.78 to $56.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413598,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":1900,"price":56.29,"value":106951.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.78 to $56.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":118485,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413597,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":1800,"price":54.91,"value":98838.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.64 to $55.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":120385,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413596,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":1210,"price":53.98,"value":65315.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.59 to $54.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":122185,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413595,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":4400,"price":53.15,"value":233860.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.55 to $53.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":123395,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4413594,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-02T02:59:52.000Z","date":"2017-02-27","kind":"exercise","acquired":true,"shares":10000,"price":1.35,"value":13500.0,"ownership":{"direct":true},"balance_after":127795,"source":{"system":"sec-edgar","filing":"0001209191-17-016244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117016244/doc4.xml","form_type":"4"}},{"id":4473308,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to  Buy)","published_at":"2017-02-02T00:09:17.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter."}],"balance_after":215394,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-006873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117006873/doc4.xml","form_type":"4"}},{"id":4473307,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":33881,"kind":"person","name":"BUTITTA CYNTHIA M","position":1,"cik":"0001222082","reported_name":"BUTITTA CYNTHIA M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-02-02T00:09:17.000Z","date":"2017-01-31","kind":"sale","acquired":false,"shares":10000,"price":50.5562,"value":505562.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":117795,"source":{"system":"sec-edgar","filing":"0001209191-17-006873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1222082/000120919117006873/doc4.xml","form_type":"4"}}],"next_cursor":"2017-02-02T00:09:17.000000Z,4473307"}